• ISSN : 2231 - 0541 (Online)
  • 0976 - 3090 (print)
  • NLM ID : 101613942
  • CAS CODEN : PHARN8
  • Frequency : Bi-Monthly

A REVIEW ON SUSTAINED RELEASE INJECTABLE DEPOT DRUG DELIVERY SYSTEMS

A REVIEW ON SUSTAINED RELEASE INJECTABLE DEPOT DRUG DELIVERY SYSTEMS

The proper management of some diseases has been shown to be dependent upon achieving consistent pharmacokinetic profiles, which is reliant on the timing of dosages, paired with the total compliance of the patient. For many specific patient populations compliance with daily oral dosing presents inherent complications. However, patients receiving continuous (i.e., extended release) therapies have been shown to have lower rates of relapse, because of the constant dosing of medication.Increasing the treatment length of a dose given by injection and finding preferential ways to deliver extended-release therapies are the basis for continued research in the formulation of extended or
sustained-release injection products. In many cases, trying to avoid a parenteral (injectable) route of administration through oral dosing is not feasible or even desirable. Therefore, the development of many sustained-release drug products results in injection-based products. Extending the release of a drug may be achieved through the manipulation of physiochemical properties, the use of formulation
technologies such as microspheres and nanospheres, and balancing the in vivo properties of the compound (such as half-life). This review will cover current options for developing extended-release pharmaceutical parenteral (injection) delivery systems including microspheres, traditional depots, and injectable implants that are currently approved or in-process of approval by the United States Food and Drug Administration. A detailed insight on the formulation of various injectable drug delivery systems is provided in this review along with an overview about the polymers and excipients mostly used in these formulations.